LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 3 | L04 | 72 | hr | 1401 | 4027 | 4545 | 0.8859 | 0.8622 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 1 | L03 | 72 | hr | 1401 | 3319 | 3978 | 0.8342 | 0.7731 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 2 | L03 | 72 | hr | 1401 | 3470 | 4213 | 0.8236 | 0.7699 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 3 | L03 | 72 | hr | 1401 | 3536 | 4545 | 0.7778 | 0.7249 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 1401 | 2682 | 3978 | 0.6741 | 0.5390 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 1401 | 2733 | 4213 | 0.6487 | 0.5228 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 1401 | 3180 | 4545 | 0.6995 | 0.6204 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 1 | L01 | 72 | hr | 1401 | 1043 | 3978 | 0.2622 | -0.1782 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 2 | L01 | 72 | hr | 1401 | 987 | 4213 | 0.2343 | -0.1981 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 3 | L01 | 72 | hr | 1401 | 1319 | 4545 | 0.2902 | -0.0351 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 1 | P24 | 72 | hr | 1401 | 2838 | 3978 | 0.7133 | 0.5979 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 2 | P24 | 72 | hr | 1401 | 3328 | 4213 | 0.7899 | 0.7239 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 3 | P24 | 72 | hr | 1401 | 3678 | 4545 | 0.8091 | 0.7653 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 1401 | 2877 | 3978 | 0.7231 | 0.6125 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 1401 | 3256 | 4213 | 0.7728 | 0.7004 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 1401 | 3663 | 4545 | 0.8058 | 0.7611 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 1 | P22 | 72 | hr | 1401 | 3031 | 3978 | 0.7618 | 0.6693 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 2 | P22 | 72 | hr | 1401 | 3446 | 4213 | 0.8179 | 0.7622 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 3 | P22 | 72 | hr | 1401 | 3643 | 4545 | 0.8014 | 0.7554 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 1 | P21 | 72 | hr | 1401 | 3002 | 3978 | 0.7545 | 0.6587 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 2 | P21 | 72 | hr | 1401 | 3300 | 4213 | 0.7832 | 0.7148 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 3 | P21 | 72 | hr | 1401 | 3914 | 4545 | 0.8610 | 0.8312 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 1401 | 3143 | 3978 | 0.7900 | 0.7101 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 1401 | 3395 | 4213 | 0.8058 | 0.7457 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 3 | P20 | 72 | hr | 1401 | 3924 | 4545 | 0.8632 | 0.8340 |